#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fibrodysplasia ossificans progressiva Endocrine ophthalmopathy Narcolepsy Bulbospinal muscular atrophy congenital Hypocalcaemia Gaucher's disease type III Dementia Mitochondrial DNA depletion B-cell lymphoma refractory Thalassaemia alpha Bronchopulmonary aspergillosis Leukodystrophy Ehlers-Danlos syndrome White matter lesion Neonatal asphyxia More trials…

    Learn about Rare Diseases

    Synovial sarcoma – Treatment Prader-Willi syndrome – Diagnostics Hereditary neuropathic amyloidosis – Basic Information Urea cycle disorder – Treatment Mitochondrial myopathy Hereditary optic atrophy – Basic Information Gaucher’s disease type I – Treatment Methylmalonic acidaemia – Basic Information Hairy cell leukaemia recurrent – Trials in Disease Osteosarcoma metastatic More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Vemurafenib Fluorescein Sodium Imipramine Hydrochloride Keto-Isoleucine Calcium Specific Nucleic Acid Sna-Xfsb Fezolinetant Tulisokibart Blu-222 LTG-001 Istradefylline Ly3819469 Sodium Amivantamab Tebipenem Pivoxil Hydrobromide Dapansutrile Pseudoephedrine Hydrochloride Siponimod Fumaric Acid Ioversol Solrikitug CYCLIZINE HYDROCHLORIDE Cpft Trifluoroacetate More therapies…

    Learn about Your Condition

    Hypercholesterolaemia Cardiac arrest Notalgia paraesthetica Vulvovaginal dryness Perineal injury Chronic sinusitis Hyponatraemia Polyneuropathy Huntington's disease Metachromatic leukodystrophy Colorectal cancer stage III Embolic stroke Ear discomfort Dyspepsia Intracranial calcification More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

K-ras gene mutation

  • A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pemetrexed Disodium
    • Carboplatin
    • Cetuximab
    Finland Greece Italy The Netherlands Poland Spain

  • Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Cetuximab
    Finland France Germany Hungary Italy The Netherlands +3

  • Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • K-ras gene mutation
    • Non-small cell lung cancer
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Divarasib
    • Budesonide
    • Carboplatin
    Belgium Denmark France Germany Greece Hungary +6

  • Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Austria Belgium Denmark Finland France Germany +7

  • Study of JDQ443, TNO155, and Tislelizumab for Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    2 1 1
    Investigated Drugs:
    • 1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
    • Batoprotafib
    • Tislelizumab
    Belgium Denmark France Germany Italy The Netherlands +1

  • Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Sotorasib
    Denmark Norway Sweden
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!